December 5, 2020 Product Launch

Roche announces new data reinforcing the long-term benefit of Venclexta/Venclyxto-based combination for people with relapsed or refractory chronic lymphocytic leukaemia

             Basel, 5 December 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from the pivotal phase III MURANO and CLL14 studies support the efficacy of fixed-duration, chemotherapy-free Venclexta®/Venclyxto® (venetoclax)-based combinations in certain people with chronic lymphocytic leukaemia (CLL) and provide more evidence on the potential value of minimal residual disease (MRD).... Read more

December 2, 2020 Acad, Gov/Utilities Bio/Pharma/CRO

Roche announces FDA approval of Gavreto (pralsetinib) for people with advanced or metastatic RET-mutant and RET fusion-positive thyroid cancers

Basel, 2 December 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved Gavreto™ (pralsetinib) for the treatment of adult and paediatric patients 12 years of age and older with advanced or metastatic rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC) who require systemic therapy,... Read more

December 2, 2020 Acad, Gov/Utilities PR/Corporate Product Launch

Roche receives FDA Emergency Use Authorization for new test to measure the level of SARS-CoV-2 antibodies

Basel, 2 December 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its Elecsys® Anti-SARS-CoV-2 S antibody test has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA). The serology (blood) test can be used to measure the level of antibodies in people who have been exposed to the... Read more

December 1, 2020 Acad, Gov/Utilities

FDA approves Xolair® (omalizumab) for adults with nasal polyps

Xolair is the first biologic for the treatment of nasal polyps that targets and blocks immunoglobulin E (IgE), a key driver of inflammation Xolair is now FDA-approved across three diseases and in two formulations, continuing to build on the medicine’s 17 years of patient experience since its initial approval for allergic asthma              Basel, 01 December... Read more

November 24, 2020 Acad, Gov/Utilities Bio/Pharma/CRO

Roche announces FDA approval of Xofluza for the prevention of influenza following contact with an infected person

Xofluza is the first single-dose influenza medicine approved to prevent influenza for those who have had contact with an infected person (post-exposure prophylaxis) Roche also provides an update on the sNDA filing for Xofluza in the paediatric setting              Basel, 24 November 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food... Read more

November 16, 2020 Environ, Ag./Food & Bev

Roche ranked the most sustainable healthcare company in the Dow Jones Sustainability Indices for the eleventh time

The ranking acknowledges Roche’s commitment to sustainability as an integral part of its business strategy Roche performed particularly well in Marketing Practices, Environmental and Social Reporting, Operational Eco-Efficiency, Climate Strategy, and Corporate Citizenship and Philanthropy              Basel, 16 November 2020 – For the eleventh time, Roche (SIX: RO, ROG; OTCQX: RHHBY) has been recognised as the... Read more

November 13, 2020 Uncategorized

CHMP recommends EU approval of Roche’s Xofluza® (baloxavir marboxil) for the treatment of influenza

One-dose, oral Xofluza has been recommended for approval for the treatment of uncomplicated influenza in patients aged 12 years and above Xofluza has also been recommended for approval as a preventive treatment (post-exposure prophylaxis) of influenza in individuals aged 12 years and above If approved, Xofluza would be the first innovation in mode of action... Read more

November 13, 2020 Uncategorized

CHMP recommends EU approval of Roche’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for HER2-positive breast cancer

Phesgo offers faster and less invasive delivery of standard of care treatment with Perjeta and Herceptin, under the skin in just minutes, compared to hours with intravenous infusion1,2,3 Subcutaneous administration is preferred by patients, physicians and healthcare providers, and can be associated with reduced hospital times and costs4,5,6 This is the first time that Roche... Read more

November 5, 2020 Acad, Gov/Utilities Product Launch

Roche to present new data across 16 blood disorders at the American Society of Hematology 2020 Annual Meeting

Basel, 5 November 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data for its approved and investigational medicines will be presented at the all-virtual 62nd American Society of Hematology (ASH) Annual Meeting and Exposition from 5 – 8 December 2020. Eleven Roche medicines will be featured in more than 80 abstracts,... Read more

November 2, 2020 Uncategorized

European Commission approves Roche’s Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer

Basel, 2 November 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy. “Tecentriq in combination with Avastin is the first treatment... Read more